The DOI matches its Crossref record.
L-Asparaginase and PEG Asparaginase— Past, Present, and Future
Abstract
L-asparaginase is an enzyme which hydrolyses asparagine. Since the 1960s it has been known that some leukemic cells are deficient in asparagine synthetase and therefore cannot manufacture sufficient quantities of this essential amino acid to maintain cell viability. L-asparaginase is predominantly useful in acute lymphocytic leukemia (ALL) although responses have been noted in patients with acute myeloid leukemia, lymphoma, and rarely other tumors. L-asparaginase has been used in conjunction with methotrexate and ara-C in combination programs in leukemia. The major side-effect limiting the usefulness of L-asparaginase is allergic reactions. In addition, it is probable that neutralizing antibodies develop which shorten the half life of the drug so that the goal of depletion of plasma levels of asparagine cannot be attained or maintained. Polyethylene glycol (M.W. 5000) can be conjugated to L-asparaginase at sites not involving the active site of the enzyme. This enables free access of a small molecule, asparagine, to the active site of the enzyme but prevents uptake by the reticuloendothelial system, greatly decreasing the probability of developing antibodies against the asparaginase and prolongs the circulating half life of the drug. In a phase I/II study conducted at the M.D. Anderson Cancer Center, 37 heavily pretreated patients with refractory hematologic malignancy were treated. The age range from 15 to 73 years, median 49 years. Nineteen patients had ALL, 15 lymphoma, two myeloma, and one Hodgkin's disease. The dose levels of PEG L-asparaginase varied from 250 IU/m2 up to 8000 IU/m2. The pharmacokinetic profile demonstrated a mono-phasic half life consistent with a one compartment model with a single elimination phase. The mean t1/2 of PEG L-asparaginase was 357 hours compared with 20 hours for L-asparaginase. The major side effects were nausea and vomiting, peripheral edema, hypoalbuminemia and hepatic dysfunction. Three patients developed allergic reactions. There was no clear relationship between the dose of PEG L-asparaginase and toxicity. Three patients achieved complete remission, two with lymphoma, and one with ALL. Doses were repeated at two week intervals. Asparaginase depletion was documented to persist until the next dose. Thus PEG L-asparaginase allows for less frequent dosing, good tolerance, and persistent asparagine depletion with an acceptable toxicity profile. Further evaluation of the role of PEG L-asparaginase in patients who are documented to be hypersensitive to native L-asparaginase is indicated and additional clinical trials are being conducted to evaluate response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Self-citationTurecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640
Metadata
- Authors
- Keating, M. J., Holmes, R., Lerner, S., & Ho, D. H.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 1993-01
- Volume
- 10
- Issue
- sup1
- Pages
- 153-157
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2156945455
- Cited by
- 217
- References
- 0
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: L-Asparaginase and PEG Asparaginase— Past, Present, and Future. https://app.cochat.ai/papers/10.3109/10428199309149129
- The paper
- Keating, M. J., Holmes, R., Lerner, S., & Ho, D. H. (1993). L-Asparaginase and PEG Asparaginase— Past, Present, and Future. Leukemia & Lymphoma. https://doi.org/10.3109/10428199309149129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.